A retrospective stud analysising efficacy of adalimumab and golimumab in patients with HLA-B-27-associated uveitis
Latest Information Update: 15 Dec 2021
Price :
$35 *
At a glance
- Drugs Adalimumab (Primary) ; Golimumab (Primary)
- Indications Anterior uveitis; Intermediate uveitis
- Focus Therapeutic Use
- 15 Dec 2021 New trial record